Welcome to our dedicated page for Haoxi Health Technology SEC filings (Ticker: HAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haoxi Health Technology Limited filings document foreign private issuer reporting for a China-based online marketing solutions provider with Class A ordinary shares listed on Nasdaq. Form 6-K reports furnish interim financial statements, management discussion and analysis, material-event disclosures and exhibits tied to the company’s operating results, liquidity and shareholder equity.
The company’s regulatory record also covers auditor changes, board composition, shareholder meeting notices and proxy materials, material agreements, shelf registration and at-the-market offering documents, private placement agreements, termination of financing arrangements and capital-structure disclosures involving ordinary shares and related securities.
Haoxi Health Technology Ltd director and CEO Fan Zhen has filed an initial statement of beneficial ownership. The filing reports direct ownership of 690,800 Class B ordinary shares, par value US$0.0025 each, as of March 18, 2026. The document does not show any new purchases or sales, but establishes Fan Zhen’s existing equity stake in the company.
Haoxi Health Technology Ltd officer Li Dongxue, the company’s Chief Financial Officer, filed an initial Form 3 reporting beneficial ownership. The data provided shows no reportable transactions, holdings, or derivative positions, indicating this is a baseline regulatory disclosure rather than a trading event.
Haoxi Health Technology Ltd director Hu Chuanjie has filed an initial Form 3 insider report. The filing identifies him as a director, not an officer or ten percent owner of Haoxi Health Technology Ltd. The data provided shows no reported transactions, derivative positions, or holdings entries at this time.
Haoxi Health Technology Ltd director Liu Jia has filed an initial insider ownership report on Form 3. The filing identifies Liu Jia as a director of the company and, in the provided data, shows no reported transactions, share purchases or sales, and no listed derivative positions.
Haoxi Health Technology Limited reported a change in its board of directors. On March 6, 2026, director Jianbing Zhang resigned from the board for personal reasons, and the company stated that his resignation did not involve any disagreement over operations, policies, or practices.
The board appointed Chuanjie Hu as a new director effective the same day and determined he meets the “independence” requirements of Nasdaq and Rule 10A-3. Mr. Hu will chair the nominating and corporate governance committee and serve on the compensation and audit committees, and will not receive compensation for his board service.
Haoxi Health Technology Limited has terminated its at-the-market equity offering program with Aegis Capital Corp. The program had allowed the company to offer and sell up to $80 million of Class A ordinary shares under an effective Form F-3 shelf registration and related prospectus supplement.
Haoxi and Aegis entered into a mutual termination agreement effective February 7, 2026, ending the sales agreement and related arrangements. The company reports that it did not sell any Class A ordinary shares under this at-the-market program before it was terminated.
Haoxi Health Technology Limited established an at-the-market equity offering program that allows it to sell Class A ordinary shares with an aggregate offering price of up to $80,000,000 under its effective Form F-3 shelf registration.
The company entered into a Sales Agreement with Aegis Capital Corp., which will act as sales agent and use commercially reasonable efforts to sell shares based on Haoxi’s instructions, through methods qualifying as an “at the market offering” under Rule 415.
Haoxi will pay the sales agent a commission of 2.5% of the aggregate gross proceeds from each sale and reimburse specified expenses of up to $75,000 annually. Cayman Islands counsel Ogier provided a legal opinion confirming that shares issued under the program will be validly issued, fully paid and non-assessable.
Haoxi Health Technology Limited is offering up to $80,000,000 of its Class A Ordinary Shares through an at-the-market program with Aegis Capital Corp. acting as sales agent or principal. Aegis will sell shares on Nasdaq at prevailing prices and receive a 2.5% commission on gross proceeds. Based on a reference price of $1.56, Class A shares outstanding could rise from 58,753,028 to 110,035,079, which would significantly dilute existing holders.
The company plans to use net proceeds for general corporate purposes, including working capital, operating expenses, capital spending, potential acquisitions and business development. Haoxi is a Cayman Islands holding company whose operations run through its PRC subsidiary, Haoxi Beijing, an online marketing solutions provider focused on healthcare advertisers, which generated $32.80 million of revenue and net income of $3,876,680 for the year ended June 30, 2025.
The filing highlights substantial legal and operational risks tied to doing business in China, including evolving foreign investment, data security and CSRC overseas listing rules that could limit offerings or even render the shares worthless. It also notes potential HFCA Act delisting risk if PCAOB access to the auditor were ever restricted, PRC constraints on moving cash out of China, the absence of planned dividends, emerging growth and foreign private issuer status, and an auditor report expressing substantial doubt about the company’s ability to continue as a going concern.
Haoxi Health Technology Limited filed a Form 6-K announcing that materials for an Extraordinary General Meeting of Shareholders are available. The filing attaches the Notice and Proxy Statement as Exhibit 99.1 and the Proxy Card as Exhibit 99.2.
The company notes it is a foreign private issuer and that the Notice is not subject to SEC review and comment. Shareholders are urged to read the Notice for important details about the meeting. Copies are available on the SEC’s website at www.sec.gov and on the company’s website at http://www.haoximedia.com/.
The company, its Board, and executive officers may be deemed participants in the proxy solicitation, with additional information about their interests described in the Notice.
Haoxi Health Technology Limited closed a Regulation S private placement to non‑U.S. persons, issuing 5,217,391 Class A ordinary shares at $0.23 per share for gross proceeds of $1.2 million. The transaction closed on October 22, 2025, and net proceeds will be used for working capital and general corporate purposes.
Following the closing, shares outstanding were 7,503,028 Class A and 690,800 Class B, each with a par value of $0.0025, as of the date of this report. The shares were issued in reliance on the Securities Act’s Regulation S exemption.